Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00089583

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

Infection, Human Immunodeficiency Virus I Clinical Trial

Official title:
See Detailed Description

Clinical Trial Summary

This is a 48-week study to collect information on the safety and activity of an investigational medicine in patients, ages 2 to 18 years old, with HIV infection .

Clinical Trial Description

A 48 Week, Phase II, non-comparative, open-label, multi-cohort, multicenter study to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of GW433908/Ritonavir BID when administered to HIV-1 infected PI-Naive and experienced, Pediatric Subjects 2 to 18 years old and of GW433908 BID Administered to PI-Naive Pediatric subjects 2 to <6 years old ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00089583
Study type Interventional
Source ViiV Healthcare
Contact
Status Completed
Phase Phase 2
Start date July 2004
Completion date March 2011
View Details
See also
  Status Clinical Trial Phase
Completed NCT03327740 - PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)
Completed NCT00257621 - GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults Phase 2
Completed NCT01227824 - A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Phase 3
Completed NCT01597648 - A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™ Phase 1
Completed NCT01205243 - ZIAGEN® Post-marketing Surveillance
Withdrawn NCT01283100 - A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects. Phase 1
Completed NCT00440947 - Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection Phase 3
Completed NCT00450580 - HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults Phase 3
Completed NCT00481390 - Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients N/A
Completed NCT00549198 - KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects Phase 4
Completed NCT00242840 - Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir) Phase 3
Terminated NCT00197145 - Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects Phase 3
Completed NCT00044577 - New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects Phase 3
Terminated NCT00104429 - GW873140 In Combination With Combivir In HIV Infected Subjects Phase 2
Completed NCT01263015 - A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial) Phase 3
Terminated NCT00102778 - GW873140 In Combination With Kaletra In HIV Infected Subjects Phase 2
Completed NCT00094523 - Fosamprenavir Versus Other Protease Inhibitors Phase 3
Completed NCT00046176 - A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients Phase 3
Terminated NCT00242879 - A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults Phase 2
Completed NCT00082394 - A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV Phase 4